What is the financial impact of the manufacturing changes?

The company expects total restructuring and asset impairment charges of $155 million to $185 million. Approximately $90 million, primarily non-cash asset impairment, was recognized in Q4 2006, and the remaining amount, largely cash severance and contract terminations, will be recognized in Q1 2007.

Why is Lilly stopping construction of the Virginia plant?

Lilly has determined that its existing manufacturing sites and new capacity being built in Sesto, Italy, will be sufficient to meet projected future demand for insulin. This strategic decision allows them to optimize their manufacturing footprint.

How many employees are affected by these manufacturing changes?

The voluntary exit program at Tippecanoe Laboratories is open to up to 250 employees. The 120 employees at the Prince William County site will be offered opportunities at other Lilly locations or provided with severance packages if they choose not to stay.

What is the significance of the Zyprexa settlement?

Eli Lilly has reached settlements resolving the vast majority of remaining product liability claims related to Zyprexa, affecting an estimated over 18,000 claimants. This resolution allows the company to put a significant legal overhang behind it. A charge of $495 million was recorded in Q4 2006 for these settlements.

LLY 8-K: Financial Events

Summary

Eli Lilly and Company (LLY) filed an 8-K on January 11, 2007, detailing significant strategic decisions impacting its manufacturing operations and addressing ongoing Zyprexa litigation. The company's board approved the cessation of construction for a new insulin manufacturing plant in Prince William County, Virginia, as existing and planned capacity in other locations, specifically Sesto, Italy, is deemed sufficient to meet future demand. This move is accompanied by opportunities for affected employees to relocate or receive severance packages. In addition, Lilly is implementing a voluntary exit program for up to 250 employees at its Tippecanoe Laboratories in Indiana, citing excess capacity in small molecule active ingredient operations. These restructuring and impairment activities are expected to result in charges of $155 to $185 million, split between Q4 2006 and Q1 2007, with a portion being non-cash asset impairments. Separately, the company announced a resolution to the vast majority of Zyprexa product liability claims through settlement agreements, estimating over 18,000 claimants covered. This settlement will result in a $495 million charge in the fourth quarter of 2006.

Key Highlights

1Eli Lilly is stopping construction of its Prince William County, Virginia, insulin manufacturing plant due to sufficient existing and planned capacity elsewhere.
2A voluntary exit program will be offered to up to 250 employees at the Tippecanoe Laboratories in Indiana due to excess capacity in small molecule operations.
3Total estimated restructuring and asset impairment charges for these manufacturing changes are between $155 million and $185 million.
4These charges will be recognized in both the fourth quarter of 2006 (approximately $90 million, largely non-cash) and the first quarter of 2007 (primarily cash for severance).
5Lilly has entered into settlement agreements to resolve the majority of remaining Zyprexa product liability claims, covering an estimated 18,000+ claimants.
6A charge of approximately $495 million ($0.42 per share after taxes) will be recorded in Q4 2006 for the Zyprexa settlements.
7Approximately 1,200 identified Zyprexa claims are not included in this settlement.

ELI LILLY & Co 8-K Report, Exit or Disposal Costs (Jan 11, 2007)

Summary

Key Highlights

Frequently Asked Questions